Efficacy and safety of avapritinib in advanced systemic mastocytosis: 4-year follow-up of the PATHFINDER study.

Gotlib J, Reiter A, Radia DH, Álvarez-Twose I, Deininger MW, George TI, Panse JP, Mital A, Pettit KM, Vannucchi AM, Platzbecker U, Hermine O, Elshoury A, Livideanu C, Mesa RA, Ustun C, Triggiani M, Dybedal I, Jurcic JG, Zanotti R, Oh ST, Yacoub A, Hexner EO, Bose P, Lee SG, Sperr WR, Griffiths EA, Butler M, Lübke J, Bidollari I, Lin HM, Rylova SN, Dimitrijević S, Muñoz-González JI, DeAngelo DJ

Associations between symptoms of depression and anxiety with left ventricular hypertrophy among Hispanic/Latino participants of the Hispanic Community Health Study/Study of Latinos.

Andrade-Bucknor SN, Mesa RA, Cordero C, Schneiderman N, Mathew A, Hurwitz BE, Rodriguez CJ, Gallo LC, Rosas CE, Gonzalez S, Solomon SD, Cheng S, Daviglus M, Kansal MM, Perreira KM, Penedo FJ, Elfassy T

Pharmacy and transfusion costs of ruxolitinib and momelotinib in patients with myelofibrosis and anemia.

Gerds AT, Yu J, Tao C, Carlton R, Naim AB, Mesa RA

Social determinants of health and biological age among diverse U.S. Adults, NHANES 2011-2018.

Mesa RA, Llabre MM, Lee DJ, Rundek T, Kezios KL, Al Hazzouri AZ, Elfassy T

Real-world analysis of polycythemia vera treatment reveals nonadherence to NCCN guidelines in a large proportion of patients.

Abu-Zeinah G, Hunter AM, Shatzel JJ, Yacoub A, Qin A, Chien HL, Mesa RA

Impact of Early-Onset or Worsening Anemia in Patients with Myelofibrosis Treated with Ruxolitinib: A post hoc Analysis of the JUMP Study.

Al-Ali HK, Guglielmelli P, Harrison CN, Mesa RA, Hamer-Maansson JE, Braunstein E, Gupta V

Highlights from MPN Asia 2025: Advances in Molecular Pathogenesis and Therapeutic Strategies in Myeloproliferative Neoplasms.

Bose P, Xiao Z, Hasselbalch HC, Prchal JT, Duan M, Yacoub A, Rampal R, Kiladjian JJ, Hobbs GS, Tashi T, Shimoda K, Kirito K, Gill H, Hou HA, Lee SE, Huang J, Li B, Qin A, Yu LH, Mascarenhas JO, Mesa RA

A pharmacovigilance study of adverse events associated with polycythemia vera treatments using the FDA Adverse Event Reporting System (FAERS) database.

Reeves BN, Masarova L, Abu-Zeinah G, Hunter AM, Shatzel JJ, Qin A, Yoon CH, Cai LY, Wei YF, Mesa RA

Time Without Transfusion Reliance (TWiTR): Integrating Survival Quality Into Myelofibrosis Treatment Strategies Based on the Phase 3 SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM Trials.

Mesa RA, Talpaz M, Mazerolle F, Gorsh B, M'Hari M, Regnault A, Ellis C, Wang Z, Purser M, Liu T, Strouse B, Patnaik D

Worldwide Innovative Network (WIN) Consortium in Personalized Cancer Medicine: Bringing next-generation precision oncology to patients.

El-Deiry WS, Bresson C, Wunder F, Carneiro BA, Dizon DS, Warner JL, Graff SL, Azzoli CG, Wong ET, Cheng L, Mani SA, Safran HP, Williams C, Meissner T, Solomon B, Rubin E, Porgador A, Berchem G, Saintigny P, Onn A, Bar J, Berger R, Gantenbein M, Chen Z, Souza CP, Reis RMV, Sekacheva M, Cervantes A, Dahut WL, Annunziata CM, Gober K, Musallam KM, Al-Shamsi HO, Abu-Gheida I, Salazar R, Limaye S, Aref AT, Reddel RR, Homsi MUA, Rouf A, Dermime S, Suwaidi JA, Vlad C, Buiga R, Omari AA, Abdel-Razeq H, Oñate-Ocaña LF, Nielsen FC, Graham L, Rueter J, Joshua AM, Girda E, Libutti S, Riedlinger G, Salem ME, Farhangfar CJ, Mesa RA, Faltas BM, Elemento O, Pramesh CS, Sengar M, Aoyama S, Ikeda S, Berindan-Neagoe I, Gaddipati H, Kulkarni M, Auzias E, Gerogianni M, Wolikow N, Istolainen S, Schlafrig P, Frankel NZ, Ferraro AR, Palma J, Gimenez AP, Hernando-Calvo A, Felip E, Tsimberidou AM, Herbst RS, Tabernero J, Schilsky RL, Liu J, Lussier Y, Raynaud J, Batist G, Magidi S, Kurzrock R